JP2024516619A - 治療方法及びナチュラルキラー細胞組成物の投与方法 - Google Patents

治療方法及びナチュラルキラー細胞組成物の投与方法 Download PDF

Info

Publication number
JP2024516619A
JP2024516619A JP2023565163A JP2023565163A JP2024516619A JP 2024516619 A JP2024516619 A JP 2024516619A JP 2023565163 A JP2023565163 A JP 2023565163A JP 2023565163 A JP2023565163 A JP 2023565163A JP 2024516619 A JP2024516619 A JP 2024516619A
Authority
JP
Japan
Prior art keywords
cells
antibody
composition
administered
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516619A5 (enExample
Inventor
ガイ ディピエロ
オースティン ビグリー
Original Assignee
インダプタ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インダプタ セラピューティクス インコーポレイテッド filed Critical インダプタ セラピューティクス インコーポレイテッド
Publication of JP2024516619A publication Critical patent/JP2024516619A/ja
Publication of JP2024516619A5 publication Critical patent/JP2024516619A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
JP2023565163A 2021-04-21 2022-04-20 治療方法及びナチュラルキラー細胞組成物の投与方法 Pending JP2024516619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177956P 2021-04-21 2021-04-21
US63/177,956 2021-04-21
PCT/US2022/025651 WO2022226130A1 (en) 2021-04-21 2022-04-20 Methods of treatment and dosing of natural killer cell compositions

Publications (2)

Publication Number Publication Date
JP2024516619A true JP2024516619A (ja) 2024-04-16
JP2024516619A5 JP2024516619A5 (enExample) 2025-09-04

Family

ID=81648459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565163A Pending JP2024516619A (ja) 2021-04-21 2022-04-20 治療方法及びナチュラルキラー細胞組成物の投与方法

Country Status (8)

Country Link
US (1) US20240197783A1 (enExample)
EP (1) EP4326288A1 (enExample)
JP (1) JP2024516619A (enExample)
KR (1) KR20240111702A (enExample)
CN (1) CN117915927A (enExample)
AU (1) AU2022262606A1 (enExample)
CA (1) CA3216410A1 (enExample)
WO (1) WO2022226130A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187181B (zh) * 2023-11-08 2024-03-19 普华赛尔生物医疗科技有限公司 包被组合物的方法及其应用
WO2025245399A1 (en) * 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
CN119193483A (zh) * 2024-11-26 2024-12-27 北京国卫生物科技有限公司 一种体外高效扩增nk细胞的培养方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504540A (ja) * 2009-09-11 2013-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高度に濃縮された薬学的製剤
JP2017507953A (ja) * 2014-02-28 2017-03-23 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体との併用療法
JP2018502585A (ja) * 2015-01-27 2018-02-01 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ナチュラルキラー細胞の大量生産方法及びその方法により得られたナチュラルキラー細胞の抗癌剤としての用途
WO2019222293A1 (en) * 2018-05-14 2019-11-21 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
US20200121588A1 (en) * 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of Providing Subcutaneous Administration of Anti-CD38 Antibodies
WO2020107002A2 (en) * 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
JP2021501578A (ja) * 2016-07-25 2021-01-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6168991B1 (en) 1999-06-25 2001-01-02 Lucent Technologies Inc. DRAM capacitor including Cu plug and Ta barrier and method of forming
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
AU2020292965A1 (en) 2019-06-10 2022-01-27 Adc Therapeutics Sa Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504540A (ja) * 2009-09-11 2013-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高度に濃縮された薬学的製剤
JP2017507953A (ja) * 2014-02-28 2017-03-23 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体との併用療法
JP2018502585A (ja) * 2015-01-27 2018-02-01 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ナチュラルキラー細胞の大量生産方法及びその方法により得られたナチュラルキラー細胞の抗癌剤としての用途
JP2021501578A (ja) * 2016-07-25 2021-01-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
WO2019222293A1 (en) * 2018-05-14 2019-11-21 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
US20200121588A1 (en) * 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of Providing Subcutaneous Administration of Anti-CD38 Antibodies
WO2020107002A2 (en) * 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.80, No.16_Supplement, JPN6026006547, 2020, pages 1630 - 1630, ISSN: 0005799565 *

Also Published As

Publication number Publication date
EP4326288A1 (en) 2024-02-28
CA3216410A1 (en) 2022-10-27
WO2022226130A1 (en) 2022-10-27
CN117915927A (zh) 2024-04-19
KR20240111702A (ko) 2024-07-17
AU2022262606A9 (en) 2023-11-16
AU2022262606A1 (en) 2023-11-09
US20240197783A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
US20260043006A1 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
US20240316102A1 (en) Engineered natural killer (nk) cells and related methods
CN112839666A (zh) 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
JP2021523122A (ja) キメラ抗原受容体（ｃａｒ）ｔ細胞療法とキナーゼ阻害剤の併用療法
US20230190801A1 (en) Natural killer (nk) cell compositions and methods for generating same
US20240197783A1 (en) Methods of treatment and dosing of natural killer cell compositions
CN115768443A (zh) Cd19定向嵌合抗原受体t细胞组合物和方法及其用途
US20250375524A1 (en) Combination of engineered natural killer (nk) cells and antibody therapy and related methods
KR20230135593A (ko) 면역 세포를 형질도입하는 방법
WO2025245399A1 (en) Method of treating cancer with natural killer cells
CN117915929A (zh) 工程化自然杀伤（nk）细胞和相关方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220